The ELF™ Test* available on the Atellica® IM Analyzer and ADVIA Centaur® Immunoassay systems is a non-invasive blood test that measures three direct markers of fibrosis: hyaluronic acid (HA), procollagen III amino-terminal peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1). The ELF Test, in conjunction with other laboratory and clinical findings, can be used to assess the risk of progression to cirrhosis and liver-related clinical events (LREs) in patients with chronic liver disease.1
- Access non-invasive testing with a simple blood test available to all healthcare practitioners and patients, including those with type 2 diabetes mellitus and obesity.2,3
- Improve patient care by identifying non-alcoholic fatty liver disease (NAFLD) patients and stratifying those at risk of progressing to cirrhosis and LREs.1
- Enhance prognostic patient management with a test that has been shown to outperform biopsy for the risk assessment of progression to cirrhosis and LREs.1
The performance of the ELF Test for liver fibrosis has been well-established in scientific literature, and ease of testing and interpretation support routine clinical use as an alternative to invasive biopsy.
The ELF literature compendium highlights a small subset of the extensive number of ELF publications and introduces the clinical utility of the ELF Test.
